Therapeutic Classification: antineoplastics
Pharmacologic Classification: monoclonal antibodies, antitumor antibiotics
High Alert
Absorption: IV administration results in complete bioavailability.
Distribution: Binds to CD33 receptor sites, is then internalized by leukemic cells, releasing ozogamicin.
Half-Life: 62 hr (↑ with second dose).
Contraindicated in:
Use Cautiously in:
CV: QT INTERVAL PROLONGATION, tachycardia
Derm: rash
F and E: hypokalemia, hyponatremia, hypophosphatemia
GI: constipation, mucositis, nausea, vomiting, ↑bilirubin, diarrhea, HEPATOTOXICITY(INCLUDING VENO-OCCLUSIVE LIVER DISEASE)
GU: ↓fertility
Hemat: anemia, BLEEDING, neutropenia, thrombocytopenia
Neuro: headache
Resp: pulmonary edema
Misc: chills, fever, ANAPHYLAXIS, INFECTION, INFUSION REACTIONS, tumor lysis syndrome
Newly Diagnosed CD33Positive AML (in combination with chemotherapy)
Newly Diagnosed CD33Positive AML (as monotherapy)
Relapsed or Refractory CD33Positive AML (as monotherapy)
Lab Test Considerations:
IV Administration: